EW - Edwards Lifesciences Corp Stock Analysis
Edwards Lifesciences Corp (EW) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 51.48B, generates annual revenue of 6.51B, and reports net income of 979.90M. As of the latest data, the stock is trading at 89.32 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at No Data (None), indicating current market sentiment. Institutional ownership is reported at 88.73%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 13.62%, trading within a 52-week range of 72.30 - 96.29.
EW - Edwards Lifesciences Corp
89.32
Analyst Consensus
No Data None
EW – Analyst Rating Summary
No analyst data available
No Data
| Index: | S&P 500 | P/E: | 53.00 | EPS (ttm): | 1.69 | Insider Own: | 1.29% | Shs Outstand: | 576.60M | Perf Week: | 2.76% |
| Market Cap: | 51.48B | Forward P/E: | 26.40 | EPS next Y: | 3.38 | Insider Trans: | -2.69% | Shs Float: | 568.38M | Perf Month: | -4.61% |
| Income(ttm): | 979.90M | PEG: | 1.88 | EPS next Q: | 0.74 | Inst Own: | 88.73% | Short Float: | 2.00% | Perf Quarter: | 7.36% |
| Revenue(ttm): | 6.51B | P/S: | 7.91 | EPS this Y: | 17.19% | Inst Trans: | 0.80% | Short Ratio: | 2.26 | Perf Half Y: | 11.97% |
| Book/sh: | 18.41 | P/B: | 4.85 | EPS next Y: | 12.78% | ROA: | 7.16% | Short Interest: | 11.35M | Perf Year: | 13.62% |
| Cash/sh: | 7.38 | P/C: | 12.10 | EPS next 5Y: | 14.03% | ROE: | 9.26% | 52W Range: | 72.30 - 96.29 | Perf YTD: | 4.77% |
| Dividend Est.: | - | P/FCF: | 35.91 | EPS past 3/5Y: | -9.46% 6.79% | ROIC: | 8.67% | 52W High: | 96.29 -7.24% | Beta: | 0.85 |
| Dividend TTM: | - | Quick Ratio: | 3.77 | Sales past 3/5Y: | 4.08% 6.70% | Gross Margin: | 78.28% | 52W Low: | 72.30 23.54% | Perf 5Y: | -22.47% |
| Dividend Ex-Date: | - | Current Ratio: | 4.52 | EPS Y/Y TTM: | 15.09% | Oper. Margin: | 28.53% | RSI (14): | 56.64 | Volatility: | 2.27% 2.69% |
| Employees: | 16000 | Debt/Eq: | 0.07 | Sales Y/Y TTM: | 14.55% | Profit Margin: | 15.05% | Recom: | 1.53 | Target Price: | 102.17 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.06 | EPS Q/Q: | -27.06% | Payout: | 0.00% | Rel Volume: | 0.53 | Prev Close: | 88.97 |
| Sales Surprise: | 2.40% | EPS Surprise: | 4.97% | Sales Q/Q: | 13.63% | Earnings: | Jul 23 AMC | Avg Volume: | 5.03M | Price: | 89.32 |
| SMA20: | 2.82% | SMA50: | 1.58% | SMA200: | 6.34% | Undervalued: 14.39% | Volume: | 2,655,742 | Change: | 0.39% | |
Graham Classic formula value: 55.48
(P/E=8 * 1g) Min value: 33.43
(current P/E * 2g) Max value: 123.01
Average value: 70.64
About Edwards Lifesciences Corp
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.